RedHill Biopharma Ltd.(RDHL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,585 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
RDHL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for RedHill Biopharma Ltd. (RDHL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RDHL at 27.3/100 on a 32-signal composite quality model, placing it at rank #2,585 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of RDHL by reported 13-F value include Yorkville Advisors Global, GAGNON SECURITIES, CITADEL ADVISORS, based on the most recent SEC filings. RDHL trades on the Nasdaq exchange and files with the SEC under CIK 1553846. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RDHL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RedHill Biopharma Ltd. directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+23.2% YoYTotal Assets
-21.7% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $8.0M +23.2% | $6.5M -89.4% | $61.8M -27.9% | $85.8M +33.2% | $64.4M +923.0% | $6.3M |
| Total Assets | $18.0M -21.7% | $23.0M -85.5% | $158.9M -12.3% | $181.2M +0.5% | $180.2M +143.2% | $74.1M |
Get alerted when RDHL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for RedHill Biopharma Ltd. including:
Top Institutional Holders of RDHL
Yorkville Advisors Global, LP
$106.7K122,131 shGAGNON SECURITIES LLC
$74.7K88,405 shCITADEL ADVISORS LLC
$55.2K65,321 shRHUMBLINE ADVISERS
$11.6K13,755 shLido Advisors, LLC
$9.3K11,009 shGAMMA Investing LLC
$5.9K6,957 shCITIGROUP INC
$3.7K4,378 shFederation des caisses Desjardins du Quebec
$2.9K3,388 shUBS Group AG
$85.00100 shSBI Securities Co., Ltd.
$13.0015 sh
| Fund | Value | Shares |
|---|---|---|
| Yorkville Advisors Global, LP | $106.7K | 122,131 |
| GAGNON SECURITIES LLC | $74.7K | 88,405 |
| CITADEL ADVISORS LLC | $55.2K | 65,321 |
| RHUMBLINE ADVISERS | $11.6K | 13,755 |
| Lido Advisors, LLC | $9.3K | 11,009 |
| GAMMA Investing LLC | $5.9K | 6,957 |
| CITIGROUP INC | $3.7K | 4,378 |
| Federation des caisses Desjardins du Quebec | $2.9K | 3,388 |
| UBS Group AG | $85.00 | 100 |
| SBI Securities Co., Ltd. | $13.00 | 15 |
More Healthcare Companies
View all Healthcare →Put RDHL on your watchlist
Track score changes the day RedHill Biopharma Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RDHL a good stock to buy?
13F Pro's AI-powered analysis of RedHill Biopharma Ltd. (RDHL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RDHL are available on the RDHL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RDHL is classified as a large company.
Which hedge funds own RDHL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RDHL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RedHill Biopharma Ltd.'s investment landscape.